AU2013295721B2 - Method of treating type I diabetes using apolipoprotein AIV - Google Patents

Method of treating type I diabetes using apolipoprotein AIV Download PDF

Info

Publication number
AU2013295721B2
AU2013295721B2 AU2013295721A AU2013295721A AU2013295721B2 AU 2013295721 B2 AU2013295721 B2 AU 2013295721B2 AU 2013295721 A AU2013295721 A AU 2013295721A AU 2013295721 A AU2013295721 A AU 2013295721A AU 2013295721 B2 AU2013295721 B2 AU 2013295721B2
Authority
AU
Australia
Prior art keywords
apolipoprotein
biologically active
apoa
active analogue
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013295721A
Other languages
English (en)
Other versions
AU2013295721A1 (en
Inventor
Xiaoming Li
Patrick Tso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cincinnati
Original Assignee
University of Cincinnati
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cincinnati filed Critical University of Cincinnati
Publication of AU2013295721A1 publication Critical patent/AU2013295721A1/en
Application granted granted Critical
Publication of AU2013295721B2 publication Critical patent/AU2013295721B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AU2013295721A 2012-07-25 2013-07-25 Method of treating type I diabetes using apolipoprotein AIV Ceased AU2013295721B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261675659P 2012-07-25 2012-07-25
US61/675,659 2012-07-25
PCT/US2013/052078 WO2014018763A2 (en) 2012-07-25 2013-07-25 Method of treating type i diabetes using apolipoprotein aiv

Publications (2)

Publication Number Publication Date
AU2013295721A1 AU2013295721A1 (en) 2015-02-05
AU2013295721B2 true AU2013295721B2 (en) 2017-07-20

Family

ID=48916270

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013295721A Ceased AU2013295721B2 (en) 2012-07-25 2013-07-25 Method of treating type I diabetes using apolipoprotein AIV

Country Status (6)

Country Link
US (1) US9730980B2 (enExample)
EP (1) EP2877197A2 (enExample)
JP (1) JP2015524808A (enExample)
AU (1) AU2013295721B2 (enExample)
CA (1) CA2878695A1 (enExample)
WO (1) WO2014018763A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG191992A1 (en) 2011-01-19 2013-08-30 Univ Cincinnati Apolipoprotein aiv as an antidiabetic peptide
EP2804618B1 (en) 2012-01-19 2018-03-07 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
WO2014018079A1 (en) 2012-07-25 2014-01-30 University Of Cincinnati Method of treating hyperglycemic disorders using apoliprotein aiv

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
FR2686605B1 (fr) 1992-01-27 1994-03-11 Rhone Poulenc Rorer Sa Nouveaux polypeptides, leur preparation et leur utilisation.
AU7242394A (en) 1993-05-28 1994-12-20 Merck & Co., Inc. Method to control appetite and treat obesity
US20060293225A1 (en) * 2001-07-26 2006-12-28 Genset S.A. Gmg-2 polynucleotides and polypeptides and uses thereof
EP1432803B1 (en) * 2001-10-05 2007-12-12 Serono Genetics Institute S.A. Fragments of the human zn-alpha2-glycoprotein and their use in methods of treatment of obesity
EP1556413A4 (en) 2002-05-17 2009-07-08 Esperion Therapeutics Inc METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC REPERFUSION
KR20060125916A (ko) * 2004-03-01 2006-12-06 펩팀문, 인코포레이티드 자가면역 질병을 치료하기 위한 방법 및 조성물
TW200815377A (en) * 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
US20100267052A1 (en) 2006-09-01 2010-10-21 American Type Culture Collection Compositions and methods for diagnosis and treatment of type 2 diabetes
CA2719001A1 (en) 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
CN103788043B (zh) 2008-11-28 2016-02-03 中国医学科学院药物研究所 硝克柳胺化合物晶iv型、其制法和其药物组合物与用途
PL2498802T3 (pl) * 2009-11-13 2015-06-30 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
SG191992A1 (en) * 2011-01-19 2013-08-30 Univ Cincinnati Apolipoprotein aiv as an antidiabetic peptide
EP2804618B1 (en) 2012-01-19 2018-03-07 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
WO2014018079A1 (en) 2012-07-25 2014-01-30 University Of Cincinnati Method of treating hyperglycemic disorders using apoliprotein aiv

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN S SUEN ET AL, "The potential of incretin-based therapies in type 1 diabetes", DRUG DISCOVERY TODAY, vol. 17, no. 1, doi:10.1016/J.DRUDIS.2011.08.017, ISSN 1359-6446, (201201), pages 89 - 95, (20110906) *
FEI WANG ET AL, "Apolipoprotein A-IV improves glucose homeostasis by enhancing insulin secretion", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES - PNAS, NATIONAL ACADEMY OF SCIENCES, 2012, vol. 109, no. 24, pages 9641 - 9646 *
VAN BELLE TOM L ET AL, "Type 1 diabetes: etiology, immunology, and therapeutic strategies.", PHYSIOLOGICAL REVIEWS JAN 2011, (201101), vol. 91, no. 1, ISSN 1522-1210, pages 79 - 118 *

Also Published As

Publication number Publication date
US20150164986A1 (en) 2015-06-18
US9730980B2 (en) 2017-08-15
WO2014018763A2 (en) 2014-01-30
CA2878695A1 (en) 2014-01-30
WO2014018763A3 (en) 2014-03-20
JP2015524808A (ja) 2015-08-27
AU2013295721A1 (en) 2015-02-05
EP2877197A2 (en) 2015-06-03

Similar Documents

Publication Publication Date Title
US20240207207A1 (en) Methods for mitigating and preventing proteostasis-based injuries
US20250154199A1 (en) Peptides for treating pain or reducing pain sensitivity
EP3658157B1 (en) Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap)
AU2013295721B2 (en) Method of treating type I diabetes using apolipoprotein AIV
EP1869080A2 (en) Human leptin-derived polypeptides and uses thereof
WO2023094581A1 (en) Compositions for the treatment of glioblastoma
EP3178485A1 (en) Socs1-derived peptide for use in chronic complications relating to diabetes
AU2012385960B2 (en) Method of treating hyperglycemic disorders using apolipoprotein AIV
KR20230159847A (ko) 염증성 또는 활성화된 세포를 표적으로 하고 염증성 상태 및 통증을 치료 또는 개선하기 위한 조성물 및 방법
US20070218504A1 (en) Human leptin-derived polypeptides and uses thereof
KR101105125B1 (ko) 클러스터린을 이용한 체중 조절 장애 관련 질환의 진단, 예방 또는 치료 방법
KR101752961B1 (ko) 인테그린 알파3 베타1 저해제를 유효량 포함하는 당뇨병성 망막병증 치료용 조성물 및 치료용 조성물 탐색 방법
US20220033470A1 (en) Compositions Comprising Sortilin-1
CN114432333B (zh) MiR-503簇海绵在制备用于治疗2型糖尿病药物中的应用
CN104511028B (zh) Klf9基因在抑制肝癌中的应用
WO2020237803A1 (zh) Mrg15蛋白或基因作为靶点在代谢疾病治疗和预防中的应用
US20160108376A1 (en) Abhd5 and partial hdac4 fragments and variants as a therapeutic approach for the treatment of cardiovascular diseases
JP2011219375A (ja) オルニチンアミノトランスフェラーゼ酵素活性阻害剤の使用
WO2006123644A1 (ja) 低酸素ストレス応答に関与するInt6タンパク質、およびその利用
HK40037093B (en) Peptides and other agents for treating pain and increasing pain sensitivity
HK40037093A (en) Peptides and other agents for treating pain and increasing pain sensitivity
Kalatzis Dual CRALBP isoforms unveiled: iPSC-derived retinal modelling and AAV2/5-RLBP1 gene transfer raise considerations for effective therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired